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Introduction
The utility of controlled release medication formulations 
lies in their ability to keep drugs at steady levels in the 
blood plasma of recipients and within the termini of the 
maximum and minimum effective therapeutic levels. 
This avoids the “ups” and “downs” of medication levels 
within the body which would have been the result had 
conventional immediate release tablets been administered 
instead. In the veterinary field, controlled release medi-
cations are essential1 because of the logistical difficulties 
of administering drugs on a regular (e.g., daily) basis to 
animals. The chief advantages of controlled release vet-
erinary medications lie in the ease with which they can be 
administered; decrease in stress for animals, owing to less 
need for rounding up and frequent dosing; and, most im-
portantly for farmers, the reduced cost of treatment rela-
tive to that for a multiple dosage regime.
Polyethylene oxide (PEO) is considered a valuable mate-
rial in controlled release drug delivery science in the hu-
man field of medicine because drugs can diffuse through 
the viscoelastic mass that PEO forms upon gelation by 
water. In addition to this important property, PEO can also 
be used as a flocculent, viscosity-inducing agent, as a lu-
bricant as well as a dispersant and water retention agent.2 
The basic structural unit of the PEO polymer is the eth-
ylene glycol skeleton, which can be written as HO-(CH2-
CH
2
-O)
n
-H. PEO grades (and the nomenclature for these) 
are determined by the molecular weight of the polymer. 
Below 25,000 Da, PEOs are termed polyethylene glycols 
or “PEGs”. 
The use of PEOs and PEGs in pharmaceutical products is 
increasing because of their widening acceptance by phar-
maceutical regulation agencies. This is attributed to PEOs 
and PEGs having good physical and chemical stability, 
dissolving easily in water over time, and possessing the 
ability to be compressed. Owing to their relatively low 
melting point (ca. 70 ºC) , the higher molecular weight 
PEO polymers like PEO-303 (as supplied by DOW 
Chemicals), which has a molecular weight of approxi-
mately 7,000,000 Da, are amenable to hot melt extrusion 
(HME) to produce cylinders or tablets which can incor-
porate other materials like the active drug and excipients. 
Pharmaceutical hot melt extrusion (HME), a widely used 
method in the plastics processing industry, involves the 
physical mixing of a drug and carrier at the fusion temper-
atures of the carrier (usually a polymer). Several publica-
tions have focussed on this use.3-8 Some reports involving 
HME focus on addressing the challenges of increasing the 
dissolution rate of poorly water-soluble drugs in develop-
ing dosage forms6. Other reports discuss the advantages of 
HME being a more efficient and cost effective method for 
manufacturing various dosage forms.7 A previous study 
looked more at manufacturing issues, such as the pursuit 
of uniform cylindrical shape and homogeneous density.8 
It also looked at additives which could influence mechani-
cal and dissolution properties of the extruded substance 
which have a bearing on its usefulness as a controlled re-
lease drug delivery device. 
In the present study, we have sought generally to investi-
gate the innovative use of melt-extruded PEO rods con-
taining commonly used drug substances, with a view to 
its potential application in extended release drug deliv-
ery for the treatment of bovine mastitis in the veterinary 
sector. Mastitis is an intramammary infection common 
in lactating cows9 which is of particular concern in the 
agricultural sector of countries with major dairy farming-
based economies. In New Zealand, this is particularly so 
because the clinical and subclinical forms of mastitis can 
bring about significant financial losses caused by lower 
milk production (from rejected milk), lower milk quality 
(leading to lower value due to degradation), loss of valu-
able bovine breeding stock (owing to the need to elimi-
nate infected animals), as well as the associated medical 
and labour costs with treatment or management of the 
condition in a commercial dairy herd. 
Teat treatment options have been widely reported in the 
science literature. For example, patents from the mid 
1970s10 have described “bovine teat dip” or “aqueous 
compositions to aid in the prevention of bovine mastitis”. 
“Teat seals” are contemporarily used and are usually ap-
plied to cows that have dried off. In such a treatment, the 
teat of the cow is infused with two syringes: one which 
contains an antibiotic like cloxacillin and the second con-
taining some inorganic salts in an oily base which serve to 
seal the teat so blocking off access to the udder by mastitis 
bacteria during the dry period. Teat seals containing ei-
ther reduced antibiotic levels or no antibiotic levels have 
been reported to be successful at combating the incidence 
of mastitis in dairy herds in past studies.11 The drive for 
reducing the antibiotic levels has emerged from concerns 
for the overuse of antibacterials in combating mastitis.11 
The use of viscoelastic gels such as PEO or PEG for teat 
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seals has obvious advantages in that not only can the gel 
function as a physically soft barrier seal but also it poten-
tially provides a matrix for the extended release of various 
medications such as antibiotics or other types of medica-
tion into the mammary gland. In particular, the melt ex-
trusion process can produce lengths of PEO/drug rods di-
rectly that could possibly be used for teat sealing purposes 
by direct insertion into the teat channel. 
It is thus of interest to investigate the conditions under 
which such extruded PEO rods can be produced, and the 
factors influencing the release of drugs from such ma-
trices when they are placed in or exposed to aqueous, 
though physiological-mimicking, milieu. In the present 
work, we have thus conducted a feasibility study of the 
manufacture of the extruded rods using simple benchtop 
extruders from dry drug/PEO mixtures and the carrying 
out of a UV-based assay of drug release from the rods into 
an aqueous alcoholic medium. Studies focussed initially 
on the general behaviour of release from PEO rods con-
taining drug alone. They were then extended to probe the 
effect of excipients co-extruded with the PEO and drug to 
determine if a significantly greater extent of controlled re-
lease could be achieved. Note that this aim, qualitatively 
assessed by inspection of the UV-measured drug release 
profiles over a 24 hour period (see later), was the primary 
focus of this study rather than an in-depth assessment of 
the kinetics of release from these particular rods, which 
should only be attempted in a carefully designed and con-
sidered study involving larger data sets for release of drug 
than have been used in the present study. 
In the course of the work some important manufacturing 
issues were also identified when certain excipients were 
incorporated. These have also been covered, as they were 
regarded as useful observations for future development 
of this field. A wide range of excipients was considered 
for inclusion in the PEO/drug extrudates with the express 
intention of creating a useful material from a veterinary 
point of view (i.e., a device that could offer controlled 
release over many hours or even days if possible), com-
pared to several hours. In attempting to cover all feasible 
options to achieve this goal, a wider range of excipients 
than might have been considered in earlier literature on 
PEO HME-related topics had to be employed. This has 
led to some useful observations on their actual or apparent 
effects in trying to retard PEO gelation, with one aspect 
not directly discussed in this publication but covered in a 
presentation in the 2011 NZIC conference held in Ham-
ilton,12 being studied further for commercial application. 
Materials and Methods
Most chemicals (polyethylene oxide-303, molecular 
weight of 7,000,000 (PEO-303, DOW), the individual 
drugs, buffer salts, excipients and ethanol) were sourced 
from commercial suppliers as either Analytical grade or 
laboratory grade reagents. Diazepam, hydrochlorothia-
zide, naproxen sodium, and chlorpheniramine maleate) 
were kindly donated by Douglas Pharmaceuticals, West 
Auckland, New Zealand) and were used without further 
purification. 
Determination and testing (for adherence to Beer’s 
Law behaviour) of candidate drugs that could be 
co-extruded with PEO for release studies
By consulting pharmacopoeia,13 a range of drugs was 
decided upon for incorporation into PEO by melt 
extrusion. These are summarised in Table 1. After 
sourcing the drugs, they were checked for their solubility 
in either water (initially for some drugs) or in 40% (v/v) 
AR grade (Rhone Poulenc) ethanol, and accurately 
known concentrations of them were prepared and then 
scanned using a Biochrom �ibra S12 �� spectrophotom-
eter. This was done to determine: 1) the characteristic ��/
�is spectrum of the drug over 200-400 nm to check if 
it conformed with that shown in the pharmacopoeia and 
2) to check that a reasonably linear Beer’s �aw plot of 
UV absorbance (at a chosen absorption maximum in the 
drug’s spectrum) versus concentration of the drug was 
obtained within certain concentration limits. The results 
of 2) also led to a graphical slope value which could be 
Table 1. Drugs used in the release studies from extruded PEO rods13. 
Drug UV absorption maximum 
(λmax) / nm in 40% EtOH
Melting point/ oC Therapeutic use
Sodium Salicylate 296 300 oC , Analgesic
Progesterone 246 126-131 oC Progestational steroid
Hydrochlorothiazide 271 268 oC (decomposes)  Diuretic
Diazepam 254 131-135 oC Tranquilliser
Chloropheniramine Maleate 263 130-135 oC Allergy treatment
Methyl Paraben 257 125-128 oC Preservative
Ethyl Paraben 257 115-118 oC Preservative
Propyl Paraben 257 95-98 oC Preservative
Bromazepam 235, 260 247 oC Tranquilliser
Metoprolol Succinate 222, 274 120 oC β-Adrenoceptor blocking agent
Naproxen Sodium 226, 263, 267, 271, 317, 331 156 oC Analgesic
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used in future studies for calculating concentrations of the 
drug in receptor media in which it had been released from 
gelled PEO extruded rods. 
A list of the drugs used in this study together with their 
melting points and UV absorption maxima is given in 
Table 1. Although this research was done with a view to 
applying it to the manufacture of teat seals and for the 
treatment of mastitis in cows, the drugs chosen for study 
were not ones which would be considered for treating 
mastitis. This was because we wanted to know in general 
the extent to which the gelation chemistry of melt-extruded 
PEO could be modified to influence release. Hence the 
choice of drugs used in the study was chiefly based on 
their different molecular characteristics (e.g., difference 
in polarities), with the main aim being to test how well 
they were released from the rods into a receptor medium 
when they were co-extruded with PEO either on their own 
or with various excipients. They were also chosen on the 
basis of their solubilities in the 40% v/v ethanolic release 
solvent used (see later). 
Manufacturing of the Extruded Rods
It was important for this research to develop a reliable 
bench scale manufacturing method for the melt extruded 
rods from polyethylene (oxide). This was achieved using 
a small bench-sized (in-house manufactured) extruder 
which had a heating unit wrapped around a stainless steel 
augur screw that was heated through a programmable 
ATHENA temperature controller (Fig.1)
Fig.1. Upper: The extruder and heating jacket (dark-coloured 
screw attached to barrel with wires). Lower: The ATHENA ex-
truder temperature control unit.
The methodology for using the extruder to form the ex-
truded rods was as follows. By means of a vice clamped 
to the edge of a lab bench, the augur screw and heating 
unit shown in the upper part of Fig. 1 was assembled by 
inserting the augur screw into the cylinder shaped bar-
rel with heating jacket and held firmly in place with the 
clamp. The heating jacket was plugged into the heating 
unit (with heating initiated by setting to 80-100 oC) and 
a well-mixed powder consisting of PEO (plus drugs and 
any excipients) was introduced via a spatula at the top of 
the barrel in which the augur screw had been inserted. 
The “crank handle” attached to the augur screw was then 
turned vigorously clockwise. This action caused the pow-
der to be carried down into the screw and beyond into the 
heated barrel where the PEO melted and was extruded as 
a thin rod (Fig. 2) through the small exit point at the end 
of the barrel. The residence time of the powder mix in the 
augur screw was thus brief, being less than a minute. 
Fig. 2. Typical appearance of a PEO extruded rod. The width of 
the rod was ca. 2.1-2.4 mm. These were initially extruded limp 
to the touch, but hardened rapidly on cooling to the firmness of 
a hard plastic rod. 
When the actual drugs and/or excipients (added to delay 
the onset of PEO gelation) were co-extruded with the 
PEO to form the rods, PEO powder mixes containing 
these were prepared in 30 g batches on a % (w/w) ba-
sis by accurate weighing to give ca. 1% (w/w) drug/PEO 
rods. When mixes were formulated with excipient inclu-
sion in particular, this was done with either 5% or 20% 
(w/w) excipient. In experiments where the influence of 
%(w/w) excipient on drug release was being investigated, 
10% (w/w) NaCl was included as an additional excipient. 
Before extrusion, the drug and/or excipient components 
of the powder mix were well pre-mixed by shaking in a 
pottle or a large plastic bag to maximise homogeneity. 
In using this simple extrusion methodology, the physical 
form of some of the excipients (e.g. chunky sodium chlo-
ride or calcium chloride, lumps of paraffin, etc) often pro-
vided a challenge to achieving homogeneous PEO/drug/
excipient powder mixes (see later discussion). However, 
the methodology was maintained because the % cumu-
lative concentration versus soaking time plots generated 
(see later) tended to be independent of the different rela-
tive loadings of drugs across samples, and it was the gross 
trends in drug release that were of main interest in this 
study for assessing the drug release behaviour from the 
extruded PEO rods with or without the addition of the 
various excipients. 
Samples were also prepared in which a randomly selected 
melt-extruded PEO/drug rod system (i.e., 1% metoprolol 
succinate) was also subjected to physical barrier coating 
treatments for controlling the rate of PEO gelation in the 
40% alcohol/water release medium. A barrier coating sys-
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tem containing a 25 % (w/w) combination of SPAN80 
(sorbitan mono-oleate), an excipient used for orally taken 
medical preparations, together with a tabletting excipient 
called hexaglycerol distearate or “HGDS”, was prepared. 
Coating of the co-extruded PEO/metoprolol succinate 
drug rods involved the brief dipping of the rods into the 
hot SPAN80/HGDS melt followed by air cooling until 
the coating solidified. Samples were generated where 
completely coated rods were generated but also samples 
where the bottom only or the bottom and top parts of the 
rod were left exposed (by scratching off the soft coating 
after application at ends of the rods). This led to a sub-
set of 4 samples for this particular experiment, i.e., fully 
coated, coated with one end of rod exposed, coated with 
both ends exposed and uncoated rods. Two samples per 
coating permutation were prepared. These systems were 
assessed for drug release in the receptor medium follow-
ing the same methodology described below. 
In vitro drug release test methodology
For assessing the release of drugs from the extruded 
PEO/drug/excipient rods, the extruded rods were cut into 
approximately 2-cm lengths and weighed on a 3-decimal 
place balance (Mettler). They were then affixed using 
superglue (and a wire to keep the rod approximately 
straight) to the ends of plastic spikes that had previously 
been threaded through the centre of plastic 100 m� pottle 
lids and glued in place with hotmelt-gun glue (see upper 
part of Fig. 3). The lids with attached spikes plus affixed 
rods could then be screwed onto the accompanying plastic 
100 m� pottle where fresh receptor medium (in most 
cases 40% (v/v) A.R. (Rhone-Poulenc) ethanol/water) 
was added and made up to the 100 m� mark on the pottle. 
This particular solvent medium was chosen in this study 
not only to act as a “sink” but also to simulate a biological 
membrane,14 which would possess both hydrophobic and 
hydrophilic character (such as the inside of a cow’s teat 
or a bovine vaginal membrane) so that an implant such as 
a melt-extruded rod of PEO could, in practical veterinary 
treatment situations, be pressed against for release of 
drugs across that membrane. 
When rods containing a certain formulation of PEO/drug 
or PEO/drug/ excipient were assessed for release, the test 
was done in duplicate using two separate samples made 
from the same rod. The pottles with rods and receptor 
medium were then placed inside sample holders on a 37.5 
°C shaker water bath which moved from side to side (see 
lower part of Fig. 3). 
A total of four withdrawals of 10 m� of release medium 
per replicate sample from pottles for each replicate was 
done with a syringe to assess release. These were done 
roughly at one hour (1 h), two hours (2 h), three hours 
(3 h) and twenty four (24 h) hours after initiation of 
soaking. The 10 m� withdrawn at each time point was 
then replaced with an equivalent volume of solvent (40% 
ethanol) to keep the volume at a constant 100 m� during 
the release experiment. Owing to the number of samples 
being processed (i.e., withdrawn and replaced by an 
equivalent volume of fresh release medium) at a given 
time period, it was challenging to sample at exact times 
such as 1 h, 2 h and 3 h for exposure time for each sample 
so these times are nominal only. The 1 h, 2 h, 3 h, and 24 
h soaking times could be thought of as the first, second, 
third and fourth sampling points for testing release of drug 
from the extruded rods. The first three sampling points (1 
h, 2 h, 3 h), for instance, correspond in practice to soaking 
times of between 1 and 5 hours after exposing the rods to 
the release media. The final time point corresponds to an 
exposure of the sample to the release medium for at least 
24 hours. 
All 10 m� portions of withdrawn samples were placed into 
separate sealable pottles, allowed to cool and then analysed 
by UV/Vis spectrophotometry by taking absorbance 
readings at the λmax values of the particular drug released 
from the PEO/drug/excipient rod. The whole spectrum of 
the receptor medium containing the drug from 200-400 nm 
was usually scanned before measurements to ensure there 
were no significant spectral interferences from excipients 
or PEO etc. Drug concentrations in mg/� (ppm) were then 
calculated using the relevant Beer’s �aw plot measured 
for the drug being tested and % cumulative concentration 
release profiles were then plotted. The % values were 
based on the 24 h release concentration which was taken 
to be the time by which 100% release of the drug from the 
extruded rods might be expected to have occurred. This 
assumption was justified by the observation that the PEO 
portion of the extruded rods had completely disintegrated 
after immersion for 24 hours in the release medium used, 
i.e., 40% ethanol/water (see later). Often this 24 h release 
Fig. 3. Upper: Mode of attachment of extruded PEO rods to 
release media pottle lids. Lower: Pottles in the water bath for 
testing release of drug from PEO extruded rods into 40% (v/v) 
ethanol/water.
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value was used as a benchmark to assess how much the rod 
had released relative to the calculated 100% release value 
into the 100 m� release medium which was determined 
from the weight and % (w/w) of drug incorporated in the 
rod. 
In addition to soaking of extruded rods from all PEO/
drug/excipient combinations studied, an experimental 
release trial was carried out to test homogeneity of powder 
mixing of PEO/drug mixes with and without excipients 
added. The drug tested for release for this experiment 
was sodium salicylate which was added to give a value 
of ca. 1% (w/w) in powder mixes of PEO combined with 
either “cellulose CMC”, paraffin or no excipients (i.e., 
PEO alone with the drug) . Accurately weighed amounts 
(0.1-0.6 g)of these powders (i.e. they were not extruded 
into rods) were added to pottles into which 100 m� of 
40% EtOH/H2O was then added. These were sealed 
and left to stand in the dark at room temperature for 48 
hours. At the conclusion of this experiment the solutions 
were subjected to a single UV analysis at 296 nm after 
shaking to homogenise the contents of the pottles. To 
ensure complete dissolution of the powders in the release 
medium, soaking for 48 h was used instead of for 24 h. 
Results
Initial Experiments involving the extrusion of 
PEO (alone) with a wide range of drugs and soak-
ing in 40% EtOH to determine release behaviour 
Initial experiments involving the extrusion of 
PEO(alone)/1% (w/w) drug powder mixtures involv-
ing diazepam, hydrochlorothiazide, sodium salicylate, 
naproxen sodium, bromazepam, methyl (as well as ethyl 
and propyl) paraben, metoprolol succinate, chlorphenira-
mine maleate and progesterone gave favourable results 
with all extruding well at 80-95 ºC. The lengths of rod 
tested for release were generally in the range of 1.98 to 
2.08 cm, width 0.20 to 0.24 cm and weighing from 0.081 
to 0.140 g. The glue used to affix the rods to the pottle 
caps was confirmed not to dissolve in the 40% EtOH re-
lease solvent used to give any background in U.V./Vis. 
spectra. 
Generally by the first sampling point (“1 h”), the PEO/
drug rods were observed to go limp and progressively dis-
solve over the next two sampling points, albeit while still 
being attached to the pottle lids. By the time more than 
24 hours of soaking had elapsed, the rods had dissolved 
and deformed to such an extent that they had become de-
tached from the pottle lid with a diffuse mass of PEO in 
the approximate form of the rod observed to be lying on 
the bottom of the release pottle. This approximately 24 
hour sampling point was where the highest UV absor-
bance due to the released drug was usually observed. In 
fact, the concentration detected was visually levelling off 
in % cumulative concentration vs. soaking time graphs 
plotted of the release at that point (see later). It was this 
point (owing to the degraded and dissolved state of the 
extruded rod) that the cumulative concentration % release 
plots were calculated (the last point at which is invariably 
“100%”). The use of this time point at the 100% release 
was deemed mostly justifiable because a significant pro-
portion of the drug co-extruded into the rod had released 
after only the third time point for measuring release (i.e., 
up to 90 % of the expected amount based on the % (w/w) 
of drug in the extruded rod for some drugs). Hence there 
is likely to be less than 10% of the original drug amount 
still resident in the diffuse mass of PEO gel lying at the 
bottom of the release pottle after 24 h of soaking. 
Graphs of cumulative % concentration of drug 
released vs. soaking time for drugs co-extruded 
solely with PE. 
A wide range of commonly used drugs (as shown in Table 
1) were co-extruded with PEO alone at a loading level 
of approximately 1% (w/w). Two cumulative concentra-
tion % vs. time and % release vs. time plots for drugs 
with differing solubility properties in aqueous solutions 
are shown in Fig. 4, namely diazepam, which is largely 
insoluble; and Naproxen sodium, which is soluble. Both 
drugs, however, dissolved in the 40% EtOH/water release 
medium to produce UV-analysable solutions. Two curves 
per drug are shown in Fig. 4 for the diazepam/PEO sys-
tem and serve to show the consistency of release behav-
iour for each of the two replicates per drug tested. The 
shape of the curve, to which a logarithmic trend-line is 
best fitted, is strongly representative of the typical drug 
release behaviour observed throughout this study from 
the extruded rods, namely, a steep increase in drug release 
at the first, second and third time (sampling) points fol-
lowed by a plateauing or leveling off by the “24 h” time-
point. This release behaviour is obviously dominated by 
the fact that the rods swell rapidly via hydration to the 
point that they drop off the pottle lids to rest at the bot-
tom of the sampling containers.15 The same curve shape 
is observed when the actual UV measured concentration 
data from each replicate rod are plotted vs. the time of 
soaking, implying that this shape is not an artefact of us-
ing cumulative concentration as a unit. Hence, the speed 
at which gelation occurs for PEO co-extruded for drugs 
without any added excipients is leading to rapid loss of 
drug from the rods. Indeed in a study where a related 
polymer PEG6000 was co-extruded with a poorly soluble 
drug, 17β-estradiol hemihydrates,16 the PEG6000 (and 
other polymers co-extruded in separate samples) were 
found to be facilitating the transport of this relatively in-
soluble drug into solution. 
In the present study, although the cumulative concentra-
tion % release versus time plots gave very similar ap-
pearances over all drugs trialled, the actual cumulative 
concentration % release values at the first three sampling 
points did exhibit some variation, depending on which 
drugs were tested. The range of release concentrations is 
illustrated in Fig. 5 for all replicates tested of the drugs 
studied. This shows the wide variation in concentrations 
at the 1h, 2h and 3h sampling points. Progesterone, so-
dium salicylate and naproxen sodium exhibit the highest 
release over that time period, probably because of their 
higher solubilities in the release media. �alues for the % 
cumulative concentration range for all the drugs tested 
range from the about 45% to 70%. 
Visually the PEO extruded rods went limp very quick-
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ly when immersed in the release medium, as is evident 
in Fig. 6. In terms of how “accurate” the 100% release 
assumption at 24 hour sampling was concerned, Fig. 7 
shows a plot of the comparison of observed 24 hour re-
lease concentrations (in ppm) for all replicates of drugs 
illustrated in Fig. 5, with their calculated 100% release 
value based on the weight of the rod and weight percent 
of drug inside each rod and, furthermore, assuming 100% 
release of that into the 100 m� of release solvent. As is 
evident, there is a large variation of agreement between 
the calculated 100% and observed release values. Most of 
the % variance in agreement was positive, so larger con-
centrations than expected from calculated 100% release 
concentrations were actually observed. Some systems 
like PEO/chlorpheniramine maleate and PEO/metoprolol 
succinate gave extremely large positive variances, while 
a few like PEO/bromazepam and PEO/ethyl paraben gave 
negative variations for their concentrations at 24 hour 
sampling periods. The many reasons for these variations 
include inhomogeneities in drug concentration through-
out the PEO/drug extruded rod, sampling technique or 
dilution errors building up in the values calculated for the 
concentration with time owing to the need to correct the 
observed concentrations for dilution. However, with most 
%variance between -20 and +20 %, the results were seen 
as indicative. With the exception of bromazepam, the rep-
licates for each extruded drug/PEO combination behaved 
consistently with each other. 
Fig. 6. A melt-extruded PEO rod (�-shaped shadow) and its ap-
pearance after soaking in 40% EtOH/H2O for 1 hour. Lengthen-
ing and swelling of the rod as illustrated occurs rapidly within 
the first hour of soaking. 
Fig. 7. Comparison of the ��-assayed release profiles of drugs 
from extruded PEO(alone)/drug rods soaking in 40% EtOH/
H2O solutions at 37 ºC with the concentrations for the calculated 
100% release of drugs from rods into 100 m� of release solvent. 
Release at 24 h, calculated 100% release of drug concentrations 
and % variance should be read from the left to right columns 
respectively per replicate sample tested for the drugs.
Experiments in which PEO is co-extruded with so-
dium salicylate and excipients to achieve a greater 
extent of controlled release
It was obvious from experiments involving extrusion of 
drugs with PEO alone that the level of release into the 
40% EtOH/H2O medium was very rapid, to the extent 
that its use as a controlled release material for deliver-
ing a drug over a matter of days would be limited, owing 
to rapid dissipation from the gelating PEO matrix which 
Fig. 4. Cumulative concentration versus time of soaking for 
(upper) Diazepam/PEO (plots for both replicates shown), and 
(lower) Naproxen sodium/PEO co-extruded rods in 40% ethanol 
at 37ºC.
	  
	  
	  
Fig. 5. ��-assayed % cumulative concentrations measured at 1 
h, 2 h and 3 h soaking times (in 40% EtOH/H2O at 37 ºC) for re-
lease of drug from melt extruded rods of PEO (alone) with vari-
ous drugs. Sampling points for each group of 3 bars per replicate 
sample for drugs should be read from left to right.
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visibly leads to its rapid disintegration. PEO forms a hy-
drogel in aqueous solution. Hydrogels are well known for 
producing networks which can release drugs rapidly over 
periods of hours or days. Much work has been done with 
molecularly based strategies for limiting release such as 
through crosslinking.17 However, given that there is an in-
terest in finding simpler ways to do this for veterinary ap-
plications where the veterinary industry supplying these 
pharmaceuticals and the clientele using them prefer lower 
unit cost of materials utilized for such purposes, physical 
methods for delaying drug release from the PEO hydrogel 
were sought instead. Various strategies along these lines 
have been tried in the past, such as charge interactions 
between ionic type polymers and charged drugs (not ap-
plicable with PEO) and surface diffusion control, where 
a reduced permeability film resides at the surface along 
with a thermosensitive switch that may facilitate diffusion 
given changes in temperatures. The approach taken in this 
study was simpler in concept and concentrated more on 
the use of excipients co-extruded with the PEO and drug. 
Historically, excipients were defined18 as additives to a 
pharmaceutical that ensured it had the correct weight, 
consistency and volume so that administration could pro-
ceed in the way intended. This was the role expected of an 
excipient when the drug delivery vehicle was restricted to 
the traditional tablet or pill. Nowadays, with more diverse 
forms of drug delivery vehicles available, the traditional 
definition has been extended with excipients often per-
forming multiple roles when included in a pharmaceutical 
formulation. In the present study, it was desired to rein in 
the fast release characteristics of the PEO when it, alone, 
was extruded along with the drug. Hence, excipients were 
chosen so that they might compete with the PEO for water 
after immersing the extruded rods in the release medium 
(see Table 2). This, it was envisaged, should then slow 
down the rate of gelation of the PEO, hence slowing the 
release of drug from the rods. 
Thus, it was necessary to design experiments where vari-
ous excipients were added to the PEO/drug powder mix 
before extrusion, so that rods containing these could be 
manufactured and trialled for their ability to delay release 
by subjecting them to the identical protocol used for the 
systems where PEO alone was co-extruded with drug. In 
testing this simple physical method for controlling re-
lease, it was decided to trial a very wide range of possible 
candidate excipients ; a total of 10 common and novel 
compounds were co-extruded with PEO. These were 
PEG6000, cell CMC, “TONE” brand polycaprolactone, 
solid paraffin, magnesium stearate, polyvinyl(alcohol), 
arabinogalactan (oligosaccharide derived from the Amer-
ican Western �arch tree), agarose, calcium chloride and 
sodium chloride, which was added to a number of these 
as an additional excipient. At the last stage of this study 
beeswax was also tried, but was combined with PEO via 
a different empirical methodology to that used for form-
ing the PEO-extruded rods. Owing to the large number of 
excipients investigated which would have led to a large 
number of drug/PEO/excipient permutations/trials, it was 
decided to concentrate on only one drug to test the ability 
Table. 2 The primary function of excipients used as 5% or 20% w/w loadings which were co-extruded with PEO-303 
rods containing also ~1% (w/w) sodium salicylate. Rods were also co-extruded with 10 % (w/w) sodium chloride un-
less otherwise stipulated. 
Excipient Mode of action for slowing PEO-303 gelation in the release medium Co-extrudability with PEO-303
Agarose (No NaCl added) Competes with PEO for water to delay PEO gelation Good
Arabinogalactan (No NaCl added) ditto Good
Calcium chloride (No NaCl added)
Competes with PEO for water in similar manner to 
NaCl but to a greater extent owing to the influence of 
the divalent Ca2+ ion which results in a more heavily 
hydrated ion
Good
Carboxymethylcellulose
(“cell CMC”)
Competes with PEO for water  to delay PEO gelation Good
Lactose Competes with PEO for water  to delay PEO gelation Extremely poor leading to blocking of the extrusion apparatus
Magnesium stearate
Provides hydrophobic layer to delay gelation of PEO 
by water
�ery poor leading to low quality, non-
cohesive rods 
Paraffin wax ditto Good, though uniformity of mixing of 
PEO, drug + excipients is problematic
PEG6000 Competes with PEO for water to delay PEO gelation Good
P�A (polyvinyl alcohol). ditto Good
Sodium chloride (not used on its own)
Used as an adjuvant in most excipient-added samples 
to compete with PEO for water so delaying PEO 
gelation
Good, although large salt crystal size 
may not promote the best uniformity of 
mixing of solid components
TONE polycaprolactone Temporary encapsulant for PEO rod to delay access of water to PEO Good
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of these substances to delay drug release. Of the drugs 
trialled and discussed earlier, it was decided to use sodi-
um salicylate because of its rather rapid release rate from 
the PEO (only) extruded rod as shown in Fig. 5. Hence 
powder mixes consisting of ~1% by weight of drug, and 
5 or 20% by weight of excipient (remainder PEO) were 
prepared. To provide an additional amount of competition 
for gelation, it was also decided to include 10% by weight 
of NaCl in all samples (apart from arabinogalactan, aga-
rose and calcium chloride). The powder mixes were then 
extruded in the usual manner as described earlier. 
Extrusion results involving excipients
Although extruded rods could be successfully prepared 
from most PEO/Na salicylate/excipient combinations 
using temperatures of 80-100 ºC in the extruder, a num-
ber of combinations exhibited manufacturing issues. In 
particular, attempts to co-extrude PEO/drug with 20% 
lactose proved virtually impossible due to the material 
sticking intractably in the extruder. Only some segments 
could be obtained, which were insufficient for release 
testing. Co-extrusion with 20% Mg stearate at 85-90 ºC 
was also problematic because the material was too “slip-
pery”, thereby providing a barrier to extrusion of any rod 
of substance. Fragile poorly formed and/or filled rods 
were the result. Lowering the temperature of extrusion 
led to grainy and brittle rods. Rods containing 20% cell 
CMC by weight tended to extrude only above 100 ºC and 
caused some blackening in some parts of the rods pro-
duced, which had to be rejected. TONE polycaprolactone, 
while extruding to produce rods of acceptable quality, 
was a substance that was difficult to clean out of the bar-
rel of the extruder. Paraffin exhibited issues similar to 
magnesium stearate. Its slipperiness in the extruder often 
made it challenging to extrude rods efficiently, especially 
when present at 20% by weight (which may have been as-
sociated with challenges in homogenizing a powder mix 
containing that high level by weight of paraffin). 
The group of samples containing AG or agarose or CaCl2 
as excipients without NaCl could also be extruded to pro-
duce acceptable quality rods; although for samples con-
taining 20% agarose by weight, blockage of the extruder 
barrel occurred and the CaCl2-containing mixes led to 
selective “sieving/separating out” of the CaCl2 granules 
near the top of powders being introduced into the feed 
inlet of the extrusion barrel. This raises questions about 
the uniformity of excipient throughout the extruded rod 
produced (although the resultant rods were observed to 
contain speckles of the calcium salt throughout the body 
of the rod). Given the excipients existed in different phys-
ical forms from powders/granules to waxy or oily solid/
chunky materials, the issue of how uniform the rods were 
in composition when extruded from a powder mix needed 
to be considered. 
Results of release experiments. 
All extruded rods produced were tested for release with 
the usual sampling at the nominal 1 h, 2 h, 3 h and 24 h 
soaking times in 40% EtOH/H2O at 37ºC. In Fig. 8 and 
Fig. 9 bar graphs are shown for UV-detected sodium sa-
licylate concentrations measured of all replicates tested 
for each PEO/Na salicylate/excipient combination at the1 
h,2 h, 3 h and 24 h sampling points, with a comparison 
bar indicating the calculated 100% release concentration 
(in the 5th column to the right of the columns indicating 
concentrations at 1 h, 2 h, 3 h and 24 h sampling points 
from left to right in the bar graph). Data for the excipients 
used with NaCl included at 10% by weight are shown in 
Fig. 8, while Fig. 9 shows data for the excipients used 
without NaCl. For all PEO (only) / sodium salicylate rep-
licates the level of drug detected in the release medium 
after 24 h of soaking exceeds that of the expected value, 
assuming total release of all the drug into the 100 m� of 
release medium. 
Fig. 8. UV-assayed data for [Na salicylate] released from soak-
ing of extruded rods containing PEO and drug with or without 
various excipients in 40% EtOH/H2O solution at 37 ºC for 24 h. 
Columns should be read left to right for measured 24 h soaking 
and calculated 100% release for each replicate tested. 
Fig. 9. UV-assayed data for [Na salicylate] released from soak-
ing of extruded rods containing PEO and drug with or without 
various excipients in 40% EtOH/H2O solution at 37 ºC for 24 h. 
These extruded rods did not have 10% (w/w) NaCl incorporated 
into pre-extruded powder mixes. Columns should be read left to 
right for measured 1 h, 2 h, 3 h, 24 h released [Na salicylate], 
and calculated 100% release concentrations for each replicate 
tested.
These data from Fig. 8 and Fig. 9 for the PEO(alone) 
replicates reflect the rapid release of drug into the release 
medium as expected of (gelling) PEO and in line with 
the previously described release trials. The partial non-
agreement with calculated 100% release values may also 
reflect the fact that extrusion of the drug with PEO into 
rods could be compositionally non homogeneous, so that 
“1% by weight of drug in the unextruded powder” may 
not mean 1% by weight in the extruded rod. However, 
the level of agreement between the 24 h sampled concen-
trations and the calculated 100% release concentrations 
expected from the rods were within 1 ppm for the PEO 
(only)/drug samples and the behaviour of replicates was 
consistent. There will also be experimental error in the 
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calculation of the concentrations from UV assay. The most 
noticeable effect of the excipients on the disintegration of 
the PEO rod in the release medium was seen in rods ob-
served at the nominal 1 h sampling point, where most of 
the sample rods containing excipients appeared visually 
to disintegrate less relative to PEO(alone)/drug extruded 
rods. Also, in support of this, the measured values for [Na 
salicylate] at 1 h sampling were all lower than the corre-
sponding value for the [Na salicylate] released from PEO 
(alone)/drug extruded rods. This suggests a short-term in-
hibition process of PEO gelation is occurring. However, 
when rods with excipients were considered in terms of 
their release behaviour, especially the rods containing 
magnesium stearate, P�A, 20% by weight paraffin, and 
TONE PC�, the actual measured release of sodium sa-
licylate at 24 h in relation to the calculated 100% release 
of drug expected from the rods ranked the systems as 
ones of similar effectiveness to or less effective than PEO 
alone in restricting release of drug. Hence, it was obvious 
that formulation with these particular excipients did little 
to stem the release of the drug from the soaked extruded 
rods, and so were limited in any role they might have had 
as a physical barrier or as components that interfered with 
PEO gelation. Indeed the PEO/TONE PC� co-extruded 
rods were a case in point, because outwardly they gave 
the deceptive appearance of retaining their rod shape 
when observed at 1 h, 2 h and 3 h soaking times when, 
in fact, what had actually happened (as borne out by �� 
assaying) was that the PEO had leached out of the internal 
parts of the rod into the medium, leaving the TONE PC�-
encapsulating shell intact but empty. 
Other PEO/excipient combinations for which data are 
illustrated in Fig. 8 and Fig. 9 gave potentially interest-
ing results: the rods containing PEO/PEG6000, PEO/
cell CMC, PEO/ paraffin 5%, PEO/lactose 5% and PEO/
agarose (no NaCl) gave measured 24 h sodium salicylate 
concentrations which were consistently (and for some 
systems (PEG6000 and 5% paraffin) significantly below 
the calculated 100% release values expected (for both 
replicate rod samples tested). Some systems, however, 
such as the PEO/drug/5% lactose mix did give very dif-
ferent absolute values of measured [Na salicylate] values 
between the replicates which raises in these samples the 
spectre of compositional non-uniformity in the extruded 
rods as discussed above. The consistency of behaviour 
with respect to lower observed overall 24 h release con-
centrations than what is expected from calculated 100% 
release values could, however, also suggest that these par-
ticular excipients have indeed had the desired effect of 
retaining the drug within the PEO gel mass, whether it 
be through forming a physical barrier to the drug being 
released or via competing with PEO for water during the 
gelation process. Possibly, the biggest effect imparted by 
the excipient is realized in the first hour of soaking, as 
demonstrated by the visual observations on the delayed 
disintegration of the rods in the aqueous alcoholic release 
media relative to the typical, rapid PEO(alone)/drug ex-
truded rod disintegration behaviour. 
Soaking of PEO/excipient/sodium salicylate pow-
der mixes in 40% ethanol/water for 48 h
In order to determine the uniformity of the PEO/sodium 
salicylate and PEO/sodium salicylate/excipient powder 
mixes prior to extrusion, three systems were investigated 
with two replicate samples per system prepared. The sys-
tems chosen were: PEO alone with drug, PEO/NaCl (10% 
by weight)/cellulose CMC/ (20% by weight) and PEO/ 
NaCl (10% by weight)/paraffin (5% by weight). NaCl is a 
hard crystalline solid, Cellulose CMC is a powder, while 
paraffin is a chunky/waxy/oily solid; hence, these materi-
als represented the spectrum of physical dispersion types 
of excipient that were mixed with PEO in the previous 
experiments described in this study. The powder mixes 
prepared were made up identically to those made in pre-
vious release experiments except that 0.1-0.6 g of each 
of the mixed powder systems was pre-weighed into the 
release pottles used (in duplicate) without extrusion into 
rods. 100 m� of release medium was then added to these 
powdered samples and the pottles sealed. To ensure full 
dissolution and, because soaking was conducted at ambi-
ent temperatures, the powders were allowed to remain in 
the release medium for 48 h as opposed to the customary 
24 h for the rods. Furthermore, they were kept in the dark 
to prevent any spurious light-mediated decomposition of 
the sodium salicylate over this prolonged soaking time. 
After this period of time the solutions were all observed 
to be reasonably clear though viscous with some settling 
of gel on the bottom. They were shaken prior to taking 
samples for the single UV analysis. The results are shown 
for all replicates tested as a bar graph in Fig. 10. 
Fig.10. Bar graphs showing the concentration of sodium salicy-
late released from powder mixes of PEO with sodium salicylate 
(~1% w/w), cell CMC and paraffin (with each sample also con-
taining 10% (w/w) NaCl) that had been soaked for 48 h in 40% 
EtOH/H2O at ambient temperature in the dark. [NaS] = concen-
tration of sodium salicylate. Data are shown for both replicates 
per system studied. The left hand column in each group is the 
UV-assayed concentrations and the right hand column is the cal-
culated 100% release concentration expected from the weight of 
powder sampled in 100 m� of release media.
With the exception of one rod replicate sample (PEO/cell 
CMC), the pottles gave higher [sodium salicylate] values 
than expected from the calculated 100% release concen-
trations for the rods used. Dilution errors would not fea-
ture in this data as no samples were withdrawn until the 
end of the soaking period where they were assayed by 
a single �� analysis. As a consequence, no solvent was 
replaced during the 48 h soaking period. Some of the re-
sults in Fig. 10 contradict the extruded rod results in Fig. 
8 and Fig. 9, where lower concentrations than the calcu-
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lated 100% release concentrations for the rods used were 
observed for 24 h release (e.g., PEO/NaCl/paraffin 5% by 
weight, see Fig. 8). There could be several interpretations 
of these results. One is that the powder mixes, especially 
those containing chunky/ waxy excipients like NaCl and 
paraffin, exhibit compositional homogeneity issues when 
a small subset of sample (i.e., 0.1-0.6 g as in this experi-
ment) is taken from a larger prepared powder mix. The 
other interpretation, or more appropriately caveat, is that 
it may not be wise to compare results for release of drugs 
from powdered soaked samples as opposed to extruded 
rods from the same powders because the act of extrud-
ing the mix into a rod is aiding in mixing the excipients, 
sodium salicylate and PEO intimately, so that beneficial 
effects like provision of a physical barrier or competing 
with PEO for water are brought into effect, thereby stem-
ming release of drug into the release medium as intended. 
Experiments involving release from PEO/drug 
extruded rods that had been precoated with physi-
cal barrier coatings prior to immersion in the 40% 
EtOH/H2O release media
The mixed results from the PEO/drug/excipient co-ex-
truded rod studies as discussed above led to consideration 
of research trials where physical barriers were instead 
placed on the PEO/drug extruded rods as an alternative 
strategy to delay release of drug from the gelating rods. 
By placing a physical barrier via a total or partial encap-
sulation of the rod itself, it was reasoned that controlled 
release of the drug might be realized through a slow 
breakdown or erosion of the barrier film. 
In general this was trialled using 1% by weight of metopro-
lol succinate as the drug with the same release sampling 
protocol as was used in the previously described studies. 
Barrier coating systems using SPAN80 and HGDS (applied 
by dipping rods in molten mixtures of these components 
followed by rapid cooling) that involved comparison of 
release of drug from rods which were fully coated, coated 
with one end of rod exposed, coated with both ends of rod 
exposed and uncoated rods were prepared and tested. In 
short, no results from such a system were obtained because 
the barrier coating completely disintegrated and clouded 
the release medium, so rendering �� analysis impossible. 
Another barrier coating (which cannot be mentioned for 
commercial reasons) was also trialled and applied by 
dipping in molten mixtures of the barrier coating. This, 
though not clouding the medium, was found to provide a 
very weak barrier to the disintegration of the rods through 
PEO gelation. Parts of the coating were observed to have 
curled at the end of the soaking period, so providing little 
protection to the underlying PEO rod. Hence, the “rod 
coating” approach was not taken any further. 
“PEO/beeswax composites”
The research experiences and lack of success associated 
with controlling release of drug from PEO/drug/excipient 
co-extruded rods with or without barrier coatings prompt-
ed a change in research strategy with respect to achieving 
a significant (i.e. beyond 1 h of soaking) inhibition of re-
lease of drugs in matrices containing PEO. 
The change in strategy involved not preparing the ex-
truded rods but instead creating discs of co-melted PEO 
and beeswax. This work, which was initially done at the 
end of this study as a brief but successful experiment, 
showed a significant delay in the release of drug. It was 
further developed in a summer research project by BSc 
Tech student Ho Ying Yuen in 2010, who displayed the 
research as a poster presentation at a Waikato Sustainable 
Bioeconomy Student Poster conference held at the �ni-
versity of Waikato in May 2010 where she was awarded 
one of the three poster prizes offered in the competition 
decided by industrially-based judges. Commercial inter-
est was sparked in this after the conference. As a result, 
research and development of this system, albeit in a dif-
ferent direction to its original use as a drug delivery agent, 
are now proceeding with promising applications. Some of 
the disclosable results of the further study of this system 
were presented at the recent NZIC conference in Hamil-
ton in November 2011.12 
In conclusion, this empirical study has demonstrated the 
practical issues of using PEO in extruded rod systems for 
drug delivery. Fast gelation of the PEO in aqueous solu-
tions can lead to rapid release of drugs; and, apart from 
the well known strategies used by earlier workers in this 
field, simple strategies involving co-extruded excipients 
and physical barrier coatings as used in this study, may 
only have limited impact for delaying release. Further 
work concentrating on the success of the comelted PEO/
beeswax system as a delivery matrix is continuing. Some 
of the disclosable aspects of this technology will be the 
subject of a separate publication in the future. 
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